Sarah Eddy focuses her practice on patent preparation and prosecution, patent portfolio development and strategic intellectual property counseling in the life sciences and related technology sectors. Drawing on her scientific training in biochemistry, Sarah works with clients to develop and protect innovations involving biologic and small-molecule therapeutics, cell and gene therapies, nucleic acid technologies, microbiome-based products, pharmaceutical and consumer formulations and other biotechnology platforms.
Sarah has experience handling patent matters involving exosome-based delivery systems, engineered Cas proteins, antibodies and antibody-based therapeutics, CAR-T and other cellular therapies, cancer antigens, mRNA vaccines, antisense oligonucleotides, siRNA and miRNA technologies, organoids, microbiome-modulating bacterial compositions, bacteriophage therapeutics and recombinant organisms that express biologically active peptides in vivo. Her practice also includes technologies involving cosmetic, food, adhesive, polymer and advanced coating formulations. She helps clients translate technically complex innovations into commercially meaningful patent portfolios and works with inventors to identify protectable features, develop filing strategies and advance patent applications through prosecution.
Before entering legal practice, Sarah earned a PhD in biochemistry. Her scientific background allows her to engage closely with inventors, evaluate complex experimental disclosures and understand the scientific and commercial considerations affecting patent protection across biotechnology, pharmaceutical and formulation-based technologies.
Representative experience
Therapeutics
- Cell therapy technologies, including CAR-T, CAR-NK, TCR-T, engineered macrophages, engineered stem cells, iPSC-derived cell products, hematopoietic cell therapies, tumor-infiltrating lymphocytes (TILs) and regulatory T cells (Tregs), spanning cell collection and isolation, cellular engineering, receptor construct design, ex vivo modification, cell expansion and differentiation, manufacturing, formulation and cryopreservation and safety switch technologies.
- Gene therapy technologies, including adeno-associated virus (AAV), lentiviral and adenoviral vector systems, lipid nanoparticle (LNP) delivery platforms and nucleic acid therapeutics, covering vector engineering, expression constructs, targeting strategies and production and formulation methods.
- Genome engineering technologies, including CRISPR/Cas systems, zinc finger nucleases (ZFNs), TALENs, base editing, prime editing and guide RNA technologies, including editing constructs, delivery systems, target site selection and ex vivo and in vivo editing approaches.
- Antibody and protein therapeutics, including monoclonal, humanized and fully human antibodies, bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), antibody fragments (for example, Fab, scFv and VHH/single-domain formats), variable and constant region engineering (including Fc modifications), antibody-based fusion proteins, chimeric antigen receptors (CARs) and T-cell receptor (TCR) constructs, as well as receptors, ligands, cytokines, growth factors, hormones and antigen/neoantigen vaccine technologies (including mRNA, recombinant, subunit and conjugate vaccines).
- Microbiome-based therapeutics, including live biotherapeutic products (LBPs), engineered microbial therapeutics, microbial consortia, probiotic formulations and phage- and microbial metabolite-based therapies, together with microbiome-modulating agents and fecal microbiota transplantation (FMT) approaches for indications including inflammatory bowel disease, Crohn's disease, ulcerative colitis and other gastrointestinal, infectious, oncological and metabolic conditions.
Diagnostics
- Companion diagnostics and precision medicine technologies for patient stratification, treatment selection, response prediction, resistance monitoring and therapeutic efficacy assessment, involving genomic, transcriptomic, proteomic, immunological, cellular and microbiome-based biomarkers, sequencing- and PCR-based methods, liquid biopsy technologies and biomarker panels.
- Molecular diagnostic technologies involving genomic DNA, cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), mRNA and other coding and non-coding RNA biomarkers and epigenetic markers (including DNA methylation signatures), using sequencing-based methods, PCR- and qPCR-based assays, next-generation sequencing (NGS), multiplex detection and liquid biopsy platforms.
- Protein-, cell- and biomarker-based diagnostic technologies, including immunoassays, flow cytometry, immunohistochemistry (IHC), mass spectrometry-based detection, ELISA-based platforms and multi-omics approaches, as well as diagnostics based on circulating tumor cells (CTCs), immune cells and other cellular populations involving single-cell analysis and cell sorting.
Research instruments/tools
- Organoid technologies, including patient-derived organoids, stem-cell- and iPSC-derived organoids, tumor organoids and engineered organoid systems, covering induction and differentiation protocols, three-dimensional culture systems, biomaterials and scaffolds, co-culture systems, disease modeling and drug discovery platforms.
- Genomics, transcriptomics and multi-omics technologies, including next-generation sequencing, gene expression profiling and biomarker discovery.
- Cellular engineering, cell culture, cell expansion, differentiation and ex vivo cell modification technologies supporting cell therapy and organoid development.
- Microfluidic assay platforms and research tools, including droplet-generating microfluidic chips, confined-volume arrays, sample and reagent loading systems, multi-reagent assay architectures, single-cell analysis, cellular phenotype assessment, optical imaging and detection and associated data-analysis approaches for characterizing cellular responses and phenotypes.
Food science and biomass
- Microbial and animal-derived biomass technologies, including engineered microbial strains (for example, yeast, fungi and algae) and animal cell culture-based materials.
- Food science innovations, dietary supplements, nutritional products and functional food technologies.
- Consumer health, personal care and cosmetic technologies, including cosmetic and skin care formulations, bio-derived and naturally sourced functional ingredients and surfactant technologies for cleansing, emulsification, conditioning and product stability.
Chemical and pharmaceutical technologies
- Petrochemical technologies, petroleum-based hydrocarbon processing methods, refining operations and fuel additives.
Materials science and industrial technologies
- Advanced coating technologies, polymers, primers, adhesives and surface treatment processes.
Education
JD, cum laude, Indiana University Maurer School of Law, 2019
PhD, with honors, Interdisciplinary Biomedical Sciences , University of Arkansas for Medical Sciences, 2016
BA, cum laude with distinction, Biology, Hendrix College, 2011
Admissions
- Texas State Bar
- US Patent and Trademark Attorney
Speaking engagements
"The unexpected path from proteins to patents & some lessons learned along the way," 10th Annual Arkansas Undergraduate Summer Research Symposium, University of Arkansas for Medical Sciences, Little Rock, AR, July 26, 2023
Publications
- Co-author, "Obviousness-type double patenting: Best IP practices for international practitioners in view of In re: Cellect, LLC," International Federation of Intellectual Property Attorneys, November 2023
- Co-author, "Obviousness-type double patenting, terminal disclaimers and best IP practices," Norton Rose Fulbright, September 2023
- Co-author, "Full scope enablement in functional limitation claims: Supreme Court grants Amgen's petition for certiorari," Norton Rose Fulbright, November 2022
- Co-author, "Global patents comparative law guide: Sufficiency of disclosure," Norton Rose Fulbright, April 2022
- Co-author, "New linkages and extensions strengthen chains binding China's patent law: Implications for patent and regulatory approval filing strategies in China, US and Canada," Norton Rose Fulbright, February 2021
Membership and activities
- American Intellectual Property Law Association
- Austin Intellectual Property Law Association
- The Honorable Lee Yeakel IP American Inn of Court